Stereotaxis Inc
AMEX:STXS
Stereotaxis Inc
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The company is headquartered in St. Louis, Missouri and currently employs 130 full-time employees. The company went IPO on 2004-08-12. The firm's robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. The firm also offers to its customers the Stereotaxis Imaging Model S X-ray System and other accessory devices. The Genesis RMN System is designed to enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. The Odyssey Solution consolidates lab information onto an integrated display, enabling physicians to view and control all the key information in the operating room.
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The company is headquartered in St. Louis, Missouri and currently employs 130 full-time employees. The company went IPO on 2004-08-12. The firm's robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. The firm also offers to its customers the Stereotaxis Imaging Model S X-ray System and other accessory devices. The Genesis RMN System is designed to enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. The Odyssey Solution consolidates lab information onto an integrated display, enabling physicians to view and control all the key information in the operating room.
Revenue Growth: Stereotaxis expects over 20% annual revenue growth for 2025, with Q4 revenue projected to exceed $9 million.
GenesisX Approval: The company received FDA approval for its GenesisX robotic system, with a limited US launch underway and a broader rollout planned for early next year.
Recurring Revenue Momentum: Recurring revenue grew to $5.6 million in Q3 2025, driven by new catheter launches, especially the MAGIC Sweep in the US.
Strong Catheter Launch: MAGIC Sweep generated over $300,000 in its first two months, and management expects further adoption and growth.
Forward Guidance: Quarterly revenue is expected to average above $10 million in 2026, with both system and recurring revenue contributing.
Robust Innovation Pipeline: Multiple new products and partnerships, including the CardioFocus collaboration for robotic PFA, are in development.
Margin & Cost Control: Gross margin reached 55% in Q3, and the company continues to prioritize prudent expense management.
